PEGylated interferon beta-1a: Meeting an unmet medical need in the treatment of relapsing multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 777-785

  Baker, Darren P ^a   Pepinsky, Robert Blake ^a   Brickelmaier, Margot ^a   Gronke, Robert S ^a   Hu, Xiao ^a   Olivier, Kenneth ^a   Lerner, Michaela ^a   Miller, Larisa ^a   Crossman, Mary ^a   Nestorov, Ivan ^a   Subramanyam, Meena ^a   Hitchman, Stacy ^a   Glick, Gabrielle ^a   Richman, Sandra ^a   Liu, Shifang ^a   Zhu, Ying ^a   Panzara, Michael A ^a   Davar, Gudarz ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; JANUS KINASE 1; MACROGOL; NATALIZUMAB; NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN KINASE TYK2; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANTIGENICITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENCEPHALOMYOCARDITIS VIRUS; EXPANDED DISABILITY STATUS SCALE; HEPATITIS C; HUMAN; IMMUNOGENICITY; KIDNEY CLEARANCE; MULTIPLE SCLEROSIS; NONHUMAN; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROTEIN STABILITY; RELAPSE; REVIEW; SINGLE DRUG DOSE; TH17 CELL; THERAPY EFFECT; TREATMENT RESPONSE;

HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 77957359421     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0092     Document Type: Review

References (81)

1. Ahn J, Feng X, Patel N., Dhawan N, Reder AT 2004. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci '9:1547-1555.
2. Arduini RM, Li Z, Rapoza A., Gronke R, Hess DM, Wen D, Miatkowski K., Coots C, Kaffashan A, Viseux N, Delaney J, Domon B, Young CN, Boynton R. Chen LL, Chen L, Betzen-hauser M, Miller S, Gill A, Pepinsky RB, Hochman PS, Baker DP. 2004. Expression, purification, and characterization of rat interferon-β, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif '34:229-242.
3. Arduini RM, Strauch KL, Runkel L.A., Carlson MM, Hronowski X, Foley SF, Young C.N., Cheng W., Hochman PS, Baker DP. 1999. Characterization of a soluble ternary complex formed between human interferon-β-1a and its receptor chains. Protein Sci '8:1867-1877.
4. Bailon P, Palleroni A, Schaffer C.A., Spence CL, Fung W-J, Porter JE, Ehrlich G.K., Pan W., Xu Z-X, Modi MW, Farid A, Berthold W, Graves M. 2001. Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem 12:195-202.
5. Baker DP, Lin EY, Lin K-C, Pellegrini M, Petter R.C., Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L. Grant G, Whitty A, Gill A, Lindner DJ, Pepinsky RB. 2006. N-terminally PEGylated human interferon-β-1a with improved pharmacokinetic properties and in vivo effiacy in a melanoma angiogenesis model. Bioconjug Chem '17:179-188.
6. Basu A, Yang K, Wang M., Liu S, Chintala R, Palm T., Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J. Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. 2006. Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-specific mono-PEGylation. Bioconjug Chem '17:618-630.
7. Benczik M, Gaffen SL 2004. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest '33:109-142.
8. Bertolotto A, Deisenhammer F, Gallo P., Solberg Sorensen P. 2004. Immunogenicity of interferon beta: differences among products. J Neurol 251 suppl '2:II15-II24.
9. Billau A, Kieseier BC, Hartung H-P. 2004. Biological role of interferon beta in multiple sclerosis. J Neurol 251 suppl 2: II10-II14.
10. Boutros T, Croze E, Yong VW 1997. Interferon beta is a potent inducer of nerve growth factor production by astrocytes. J Neurochem '69:939-946.
11. Cohen B, Novick D, Barak S., Rubinstein M. 1995. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol '15:4208-4214.
12. tyk2 tyrosine kinase. Mol Cell Biol '14:8133-8142.
13. tyk2, an interferon-a-activated tyrosine kinase, is physically associated with an interferon-α receptor. J Biol Chem '269:3518-3522.
14. Davar G, Richman S, Hitchman S., Glick G, Subramanyam M, Hu X., Lerner M, Miller L, Nestorov I, Liu S, Zhu Y, Baker DP, Panzara MA. 2009. Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: results from two phase 1 studies. Cytokine 48:21.
15. Durelli L, Conti L, Clerico M., Boselli D, Contessa G, Ripellino P., Ferrero B, Eid P, Novelli F. 2009. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol '65:499-509.
16. Fried MW, Shiffman ML, Reddy R.K., Smith C., Marinos G, Goncales FL, Haussinger D, Diago M., Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med '347:975-982.
17. Genc K, Doan KL, Reder AT 1997. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J Clin Invest '99:2664-2671.
18. Giorelli M, Livrea P, Defazio G., Ricchiuti F, Pagano E, Trojano M. 2001. IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. J Interferon Cytokine Res '21:809-812.
19. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R., Gupta SK, Salfi M, Jacobs S. the Hepatitis C Intervention Therapy Group. 2000. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther '68:556-567.
20. Grace M, Youngster S, Gitlin G., Sydor W, Xie L, Westreich L., Jacobs S, Brassard D, Bausch J, Bordens R. 2001. Structural and biological characterization of pegylated recombinant IFN-α2b. J. Interferon Cytokine Res '21:1103-1115.
21. Guo B, Chang E, Cheng G. 2008. The type I IFN induction pathway constrains Th-17-mediated autoimmune inflammation in mice. J Clin Invest '118:1680-1690.
22. Hartung H-P, Bar-Or A, Zoukas Y. 2004. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 251 (SUPPL. 5):V12-V29.
23. Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee S.S., Balart L., Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, de Pamphilis J. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med '343:1673-1680.
24. Hussien Y, Sanna A, Söderström M, Link H, Huang YM. 2001. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol '121:102-110.
25. Huynh HK, Oger J, Dorovini-Zis K. 1995. Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol '60:63-73.
26. IFNβ Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placeobo-controlled trial. Neurology '43:655-661.
27. Jacobs LD, Cookfair DL, Rudick R.A., Herndon RM, Richert JR, Salazar AM, Fischer J.S., Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brown-scheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weinstock-Guttman B, Whitman RH; the Multiple Sclerosis Collaborative Research Group. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol '39:285-294.
28. Jensen J, Kraukauer M, Sellebjerg F. 2005. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon beta-1b. Cytokine '29:24-30.
29. Kawanokuchi J, Mizuno T, Kato H., Mitsuma N, Suzumura A. 2004. Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology '46:734-742.
30. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun A. 1993. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest '92:2602-2608.
31. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D., Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M. CHAMPIONS Study Group. 2006. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology '66:678-684.
32. Kozlowski A, Charles SA, Harris JM 2001. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 15:419-429. (Pubitemid 32783703)
33. Li X, Leung S, Kerr I.M., Stark GR 1997. Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling. Mol Cell Biol '17:2048-2056.
34. Lindsay KL, Trepo C, Heintges T., Shiffman ML, Gordon SC, Hoefs JC, Schiff E.R., Goodman ZD, Laughlin M, Yao R. Albrecht JK for the Hepatitis Interventional Therapy Group. 2001. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology '34:395-403.
35. Liu Z, Pelfrey CM, Cotleur A, Lee J.C., Rudick RA 2001. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol '112:153-162.
36. Lu HT, Riley JL, Babcock G.T., Huston M., Stark GR, Boss JM, Ransohoff RM 1995. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J Exp Med '1882:1517-1525.
37. Mager DE, Neuteboom B, Jusko WJ 2005. Pharmacokinetics and pharmacodynamics of PEGylated IFN-β 1a following subcutaneous administration in monkeys. Pharm Res '22:58-61.
38. Manns MP, McHutchinson JG, Gordon S.C., Rustgi VK, Shiffman ML, Reindollar R, Goodman Z.D., Koury K., Ling M-H, Albrecht JK; the International Hepatitis Interventional Therapy Group. 2001. Peginterferon Alfa-2b plus ribavirin compared with interferon Alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C: a Randomized Trial. Lancet '358:958-965.
39. Miller A, Lanir N, Shapiro S., Revel M, Honigman S, Kinarty A., Lahat N. 1996. Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases. J Neuroimmunol '64:151-161.
40. Muraro PA, Leist T, Bielekova B., McFarland HF 2000. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol '111:186-194.
41. Muraro PA, Liberati L, Bonanni L., Pantalone A, Caporale CM, Iarlori C, De Luca G, Farina D, Lugaresi A, Gambi D. 2004. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol '150: 123-131.
42. Nagai T, Devergne O, Mueller T.F., Perkins DL, van Seventer JM, van Seventer GA. 2003. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol '171:5233-5243.
43. Neuhaus O, Archelos JJ, Hartung H-P. 2003. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci '24:131-138.
44. Noronha A, Toscas A, Jensen MA 1993. Interferon-β decreases T-cell activation and interferon-g production in multiple sclerosis. J Neuroimmunol '46:145-154.
45. Novick D, Cohen B, Rubinstein M. 1994. The human interferon α/β receptor: characterization and molecular cloning. Cell '77:391-400.
46. Panitch HS, Bever CT 1993. Clinical trials of interferons in multiple sclerosis: what have we learned? J Neuroimmunol 46:155-164.
47. Pepinsky RB, Lepage DJ, Gill A, Chakraborty A., Vaidyanathan S, Green M, Baker D.P., Whalley E., Hochman PS, Martin P. 2001. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther '297: 1059-1066.
48. Peters M. 1996. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology '23:909-916.
49. Piehler J, Schreiber G. 1999. Biophysical analysis of the interaction of human Ifnar2 expressed in E.coli with IFNα2. J Mol Biol 289:57-67.
50. Pirhonen J, Sirén J, Julkunen I., Matikainen S. 2007. IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J Leukoc Biol '82:1185-1192.
51. Plioplys AV, Massimini N. 1995. Alpha/beta interferon is a neuronal growth factor. Neuroimmunomodulation '2:31-35.
52. Porrini AM, Gambi D, Reder T. 1995. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol '61:27-34.
53. Poser CM, Paty DW, Scheinberg L, McDonald W.I., Davis FA, Ebers GC, Johnson KP, Sibley W.A., Silberberg DH, Tourtellotte WW. 1983. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol '13:227-231.
54. PRISMS (Prevention of Relapses and Disability for Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing multiple sclerosis. Lancet '352: 1498-1504.
55. Rao HY, Li J, Zhang L.F., Chen HY, Zhu LM, Wei L, Sun Y., Wang H. 2008. Effect of PEGylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis. Zhonghua Yi Xue Za Zhi '88:96-100.
56. Reddy KR, Modi MW, Pedder S. 2002. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 54:571-586.
57. Revel M, Chebath J, Mangelus M., Harroch S, Moviglia GA 1995. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult Scler '1:S5-S11.
58. Rudick RA, Carpenter CS, Cookfair D.L., Tuohy VK, Ransohoff RM 1993. In vitro and In vivo inhibition of mitogen-driven T-cell activation by recombinant IFN beta. Neurology '43: 2080-2087.
59. Rudick RA, Sibley WA, Durelli L. 1996. Treatment of multiple sclerosis with type I interferons. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis. London: Springer-Verlag, pp 223-250.
60. Runkel L, Meier W, Pepinsky R.B., Karpusas M., Whitty A, Kimball K, Brickelmaier M., Muldowney C, Jones W, Goelz SE. 1998a. Structural and functional differences between glyco-sylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res '15:641-649.
61. Runkel LA, deDios C, Karpusas M., Betzenhauser M, Muldowney C, Zafari M., Benjamin CD, Miller S, Hochman PS, Whitty A. 2000. Systematic mutational mapping of sites on human interferon-β-1a that are important for receptor binding and functional activity. Biochemistry '39:2538-2551.
62. Runkel LA, Pfeffer L, Lewerenz M., Monneron D, Yang CH, Murti A, Pellegrini S., Goelz S, Uze G, Mogensen K. 1998b. Differences in activity between α and β type I interferon explored by mutational analysis. J Biol Chem '273:8003-8008.
63. Runmarker B, Andersen O. 1993. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain '116:117-134.
64. Schreiner B, Mitsdoerffer M, Kieseier B.C., Chen L., Hartung HP, Weller M, Wiendl H. 2004. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol '155:172-182.
65. Sen G, Lengyel P. 1992. The interferon system: a bird's eye view of its biochemistry. J Biol Chem '267:5017-5020.
66. Shapiro S, Galboiz Y, Lahat N., Kinarty A, Miller A. 2003. The "immunological-synapse" at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta. J Neuroimmunol '144:116-124.
67. Sharief MK, Semra YK, Seidi O.A., Zoukos Y. 2001. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol '120:199-207.
68. Shinohara ML, Kim J-H, Garcia VA, Cantor H. 2008. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity '29:68-78.
69. Simon JH, Jacobs LD, Campion M, Wende K., Simonian N, Cookfair DL, Rudick R.A., Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM; Whitham RH for the Multiple Sclerosis Collaborative Research Group 1998. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol '43:79-87.
70. Soilu-Hänninen M, Salmi A, Salonen R. 1995. Interferon-beta downregulates expression of VLA-4 antigen and antagonizes interferon-gamma- induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol '60:99-106.
71. Tyring SK. 1995. Interferons: biochemistry and mechanisms of action. Am J Obstet Gynecol '172:1350-1353.
72. Uze G, Lutfalla G, Mogensen KE 1995. A and b interferons and their receptors and their friends and relations. J Interferon Cytokine Res '15:3-26.
73. van Beers MMC, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, Jiskoot W. 2009. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods '352: 32-37.
74. van Seventer J.M., Nagai T, van Seventer GA. 2002. Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells. J Neuroimmunol '133:60-71.
75. Velazquez L, Fellous M, Stark G.R., Pellegrini S. 1992. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell '70:313-322.
76. Weinshenker BG, Bass B, Rice G.P., Noseworthy J., Carriere W, Baskerville J, Ebers GC 1989. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain '112:136-146.
77. Yang C-H, Shi W., Basu L, Murti A, Constantinescu S.N., Blatte L., Croze E, Mullersman JE, Pfeffer LM. 1996. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem '271:8057-8061.
78. Yong VW. 2002. Differental mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 59: 802-808.
79. Yong VW, Chabot S, Stuve O., Williams G. 1998. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology '51:682-689.
80. Zang YC, Skinner SM, Robinson R.R., Li S., Rivera VM, Hutton GJ, Zhang JZ 2004. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler '10:499-506.
81. Zeuzem S, Feinman SV, Rasenack J, Heathcote E.J., Lai M-Y, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672.